Guinea-Bissau halts newborn hepatitis B trial amid ethics backlash
A planned hepatitis B vaccine trial on newborns in Guinea-Bissau has collapsed into a high-stakes dispute over ethics, sovereignty, and the treatment of vulnerable infants in low-income settings. The study, funded by the US under Health Secretary Robert F Kennedy Jr, was designed to enroll 14,000 newborns and randomize half to receive a hepatitis B vaccine shortly after birth while the other half would not receive the shot at that time. That design quickly drew criticism because the intervention being withheld is already recommended by the World Health Organization for birth-dose protection.
The controversy now extends well beyond one protocol. It has become a public test of whether research standards accepted in one country can be imposed on newborns in another, especially when the disease burden is high and the clinical consequences of delay are severe.
Birth-dose delay carries a clear biological cost
Guinea-Bissau currently vaccinates children against hepatitis B at six weeks, not at birth. In practical terms, that leaves a window when infants can be exposed during delivery or in the early household period before they receive protection. The WHO representative in Guinea-Bissau warned that babies could encounter the virus at childbirth if their mothers are infected, then remain unprotected for weeks during a period when infection can be especially dangerous.
The liver disease risk is not abstract. Nearly a fifth of the population in Guinea-Bissau is infected with hepatitis B, and infection acquired in infancy is especially likely to become chronic. Chronic hepatitis B can progress over time to liver failure or liver cancer, and data published in 2020 placed the mortality burden at up to 25% among those chronically infected. The clinical logic behind the birth dose is straightforward: immunization at birth closes the earliest and most vulnerable exposure gap before viral transmission can take hold.
A single missed dose at birth can shape a child’s risk trajectory for decades.
Researchers sought broader effects, critics saw an unacceptable tradeoff
Bandim Health Project, the research centre in Bissau where the study was planned, said the trial was intended to examine whether hepatitis B vaccination at birth has effects beyond prevention of infection. Earlier studies in The Gambia and Guinea-Bissau had raised questions about a possible link to increased mortality, and the proposed trial was framed as a way to investigate those signals in a setting where birth-dose vaccination is not yet routine.
Yet the ethical objection was immediate and pointed. Public health experts argued that withholding a vaccine already proven to protect newborns from hepatitis B is not defensible simply because the study takes place where routine birth immunization has not yet been adopted. Walter Kazadi Mulombo, the WHO representative in Guinea-Bissau, said the central concern was that the trial would deny an established intervention to some newborns. He also noted that the vaccine has been used for more than 30 years in more than 115 countries.
The tension sits at the heart of global health research. Questions about vaccine effects beyond the primary endpoint can be scientifically legitimate, but they do not erase the immediate duty to prevent avoidable infection in newborns. In a setting with widespread hepatitis B, the control arm was never viewed as a neutral comparison by critics; it was seen as a group of infants being left exposed to a preventable hazard.
National authorities drew a hard line before enrollment began
Guinea-Bissau’s government prohibited hepatitis B vaccine trials involving children in January and asked experts from the Africa Centres for Disease Control and Prevention to help evaluate the study. Health Minister Quinhin Nantote later said the suspension remained in force and had not been overturned by the Council of Ministers, even after reports suggested the work might proceed.
His response was unusually direct. Nantote said he was surprised to learn from media reports that the study could continue and said he was outraged that he had not been informed, even though he was the minister responsible for the sector. The dispute deepened after the University of Southern Denmark said a revised protocol had received ethical approval from relevant authorities in Guinea-Bissau. Nantote denied that authorization had been granted.
No babies were enrolled and no vaccinations were administered as part of the research, according to SDU dean Jakob Grauslund. That detail matters because it places the controversy squarely in the planning and approval phase, not in a completed or partially completed clinical trial with live participant exposure. Even so, the regulatory conflict was already enough to stop the project in practice.
Ethics review, vaccine seizure, and unanswered regulatory questions
The University of Southern Denmark said its own research ethics committee gave a positive assessment, and Grauslund said the university had sought an additional independent review even though Danish law did not require one. He also said the relevant Danish statutory research ethics bodies were unable to undertake the review. Even with that approval, he stressed that Danish committee clearance did not replace the separate authorization required from Guinea-Bissau’s authorities.
On 19 October, Guinea-Bissau’s Judicial Police searched the Bandim Health Project facilities in Bissau and seized a batch of hepatitis B vaccines. Police said the batch was intended for children, but they did not specify how many doses were taken or what grounds prompted the investigation. They also said the seizure did not, by itself, mean the vaccines were defective or unsafe. The exact relationship between the seizure, the proposed trial, the importation of the vaccines, and any other regulatory issue remains unspecified in the available information.
The procedural gaps are as important as the scientific ones. A trial that depends on confidence in local authorization, national oversight, and clear protocol access cannot withstand uncertainty over whether all three were in place before the first dose was imported.
US funding and a policy climate already under strain
The proposed trial was financed by the US government at a moment when vaccine policy was already under heavy political pressure in Washington. Under Kennedy’s leadership, a US vaccine panel tried to end a longstanding recommendation that all newborns receive a hepatitis B vaccine at birth, although a federal judge later blocked that move along with other Trump administration changes to vaccine policy.
Critics questioned whether the Guinea-Bissau study could be used to support that policy shift. The available information does not show that the trial was designed to justify a change in US policy, and its stated aim was broader than infection prevention alone. Still, the optics were difficult to ignore: a government-funded newborn vaccine study, involving an intervention under debate in the United States, was planned in one of the world’s poorest countries, where the infection is common and the ethical threshold for withholding protection was already low in the eyes of many observers.
For now, the trial has been cancelled before enrollment, but the larger question is unresolved. Researchers can ask whether birth-dose hepatitis B vaccination has effects beyond preventing infection. They cannot do that credibly by placing newborns at avoidable risk without clear local approval, transparent protocol access, and a defensible reason to withhold a vaccine that protects infants during the most vulnerable hours of life.